Risk of major GI bleeding with ASA, clopidogrel, and anticoagulants

In this large meta-analysis of 61 randomized controlled trials, low dose ASA increased the risk of major GI bleeding by over 55% (OR 1.55, CI 1.27-1.90); but compared to low dose ASA, clopidogrel and anticoagulants almost doubled the odds of major GI bleeding (OR 1.86 and 1.93, respectively). The addition of a PPI to low dose ASA reduced the risk of major GI bleeding by 2/3 (OR 0.34, CI 0.21-0.57). This meta-analysis helps quantify the risks of GI bleeding with these 3 agents (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment